Disease activity in pregnant women with multiple sclerosis who discontinued treatment


  • Disease reactivity 1 year postpartum was lower among women with multiple sclerosis (MS) who suspended rituximab (RTX) treatment before pregnancy, compared with women who suspended natalizumab (NTZ) treatment, suggesting that RTX may exert long-acting effects on MS disease activity.

Why this matters

    Pregnant women with MS are required to cease drug treatment, however, newer therapies such as RTX, which possess extended biological effects, may diminish the risk of disease reactivity if taken before conception.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.